-
Posted by
Two Blokes Jun 10 -
Filed in
Stock
-
7 views
Ohtuvayre's rapid US launch has driven explosive revenue growth, with Q1 2025 sales up 95% sequentially and refill rates signaling strong patient demand. With blockbuster potential, Wall Street projects Verona Pharma's sales to reach $1 billion by 2028, fueled by its safety profile and the unmet needs of those 398 million COPD sufferers worldwide. Global expansion, robust patent protection, and a growing pipeline position Verona for sustained high-margin growth and possible buyout interest.
